Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain in high demand ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

You can reach Katie on Signal at palmer.01. Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their ...

Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy to help.” ...

Current health news covers major investments by Merck Animal Health and Gilead Sciences in the U.S., regulatory decisions ...

US President Donald Trump signed an executive order requiring drugmakers to lower prices, aligning with international rates.

Eli Lilly has filed lawsuits ... solutions for individual patient needs. The legal action also questions the safety of the compounded drugs and challenges whether the defendants are violating ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound Eli Lilly's stock wobbled Thursday after a looming coverage hit was ...

Eli Lilly shares jumped 15% after a clinical trial ... of its obesity pill candidates in late 2023, citing tolerability issues. Novo Nordisk has also faced questions about the durability and ...

Eli Lilly CEO Dave Ricks urged the Trump administration to move fast on foreign trade deals and warned of the harmful effects retaliatory tariffs could have on American exporters like Eli Lilly. In an ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...